Proxy Votes Now

Home › Funds › Amplify ETF Trust › Amplify Weight Loss Drug & Treatment ETF

Amplify Weight Loss Drug & Treatment ETF proxy voting record 2025-2026

Fund family: Amplify ETF Trust · Filed by Amplify ETF Trust (CIK 1633061) · SEC series S000085024

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 212 with, 8 against, 5 abstentions (not counted as with management). Shareholder proposals: 4 FOR, 4 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Amplify ETF Trust as a whole

The same two figures as Amplify ETF Trust’s manager page (13,713 ballot items across 28 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsAmplify ETF TrustItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)74.2%18670.4%11,728
Backed environmental and social shareholder proposals at US companiesn/a43.8%342

Where this fund voted differently from most Amplify ETF Trust funds

Each ballot item this fund voted is set against the votes of the other Amplify ETF Trust funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most Amplify ETF Trust funds on all 36 items where a comparison was possible.

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections1300
Corporate Governance234
Capital Structure170
Audit-related160
Say-on-Pay120
Compensation110
Other100
Other Social Issues32
Human Rights or Human Capital/workforce22
Shareholder Rights and Defenses10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
ELI LILLY AND COMPANYMay 4, 2026$744,012102
AMGEN INC.May 19, 2026$410,078151
REGENERON PHARMACEUTICALS, INC.June 12, 2026$351,43670
ABBVIE INC.May 8, 2026$276,96281
MERCK & CO., INC.May 26, 2026$254,789183
PFIZER INC.April 23, 2026$236,787161
ARROWHEAD PHARMACEUTICALS, INC.March 19, 2026$100,224100
SCHOLAR ROCK HOLDING CORPORATIONJune 4, 2026$89,30360

Notable votes against management

MeetingCompanyProposalFundMgmt
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposalForAgainst
May 4, 2026ELI LILLY AND COMPANYShareholder proposal to prepare an annual lobbying report. Shareholder proposalAgainstFor
May 19, 2026AMGEN INC.Stockholder proposal to require an independent board chairman. Shareholder proposalForAgainst
May 8, 2026ABBVIE INC.Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposalForAgainst
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposalAgainstFor
May 26, 2026MERCK & CO., INC.Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposalAgainstFor
April 23, 2026PFIZER INC.Adopt an Independent Chair Policy Shareholder proposalForAgainst

Search this fund’s votes by company

225 ballot items at 22 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, Amplify Weight Loss Drug & Treatment ETF voted at 22 shareholder meetings of 20 companies, on 225 ballot items in all. Where management made a recommendation, the fund followed it on 94.2% of the items and voted against it 8 times. Its most frequent area of disagreement was corporate governance (4 of its votes against management). It voted on 8 shareholder proposals. It voted FOR the board's own proposals more often than Amplify ETF Trust's funds as a whole (74.2% against 70.4%). It voted the same way as most Amplify ETF Trust funds on every item where a comparison was possible.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Amplify ETF Trust’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.